Pipeline
Initial Targeted Indications
Indication | Targeted Subgroup | Formulation | Unique selling point (USP) |
|---|---|---|---|
© Dale Biotech LLC 2021. All Rights Reserved. | |||
Compensated Cirrhosis NASH | NASH patients who have progressed to compensated cirrhosis | Injectable / Oral | Combination therapy likely to improve efficacy. Improvement in glycemic control; decreases primary drivers of fibrosis. |
Cellulite | Cellulite of lateral and posterior buttocks | subcutaneous – injectable | direct action of adipocytes |
Additional Development Opportunities
Indication | Targeted Subgroup | Formulation | Unique selling point (USP) |
|---|---|---|---|
© Dale Biotech LLC 2021. All rights reserved. | Uncontrolled Type 2 diabetes mellitus (T2DM) | Overweight and requiring insulin | Injectable | Unique short term treatment reduces body weight and improves glycemic control and reduces cardiovascular risk (CV) factors |
Body Sculpting | Double chin | Injectable | Significantly less inflammation than currently marketed injectable; Single treatment efficacy expected to be sufficient in majority of clients |
Central abdominal bulge | Injectable | No available injectable | |
Dupuytren’s Disease | Progressive contractures post hand surgery or Xiaflex injection(s) | Injectable sustained release | Large unmet medical need for effective disease modifying treatment |
Progressive contractures post hand surgery or Xiaflex injection(s) | Topical | Large market for effective treatment that can be patient-administered | |